Table 3.
Associations with the DLQI skin-related quality of life measure in psoriatic arthritis patients tested in univariate and multivariate linear regression models. Only variables with a p value <0.10 in the univariate analyses were tested in the multivariate analysis, which was adjusted for age, gender and BMI independent of their significance in the univariate analyses. Apart from age, gender and BMI, only variables with a p value <0.01 are displayed in the multivariate analysis
| Univariate analyses | Adjusted analyses | |||
|---|---|---|---|---|
| B (95% CI) | P value | B (95% CI) | P value† | |
| Age, years | −0.066 (−0.128, −0.004) | 0.037 | −0.074 (−0.128, −0.020) | 0.008 |
| Female gender | 0.232 (−1.043, 1.506) | 0.72 | −0.060 (−1.021, 1.140) | 0.91 |
| BMI, kg/m2 | 0.122 (−0.023, 0.266) | 0.01 | −0.006 (−0.132, 0.120) | 0.93 |
| Currently smoking | 0.658 (−1.076, 2.391) | 0.45 | ||
| Part-time/full-time employed/working | −1.309 (−2.581, −0.037) | 0.044 | ||
| Disease duration, years | −0.015 (−0.113, 0.082) | 0.76 | ||
| CRP, mg/L | 0.055 (−0.020, 0.130) | 0.15 | ||
| TJC68 | 0.015 (−0.042, 0.072) | 0.61 | ||
| SJC66 | −0.118 (−0.727, 0.490) | 0.70 | ||
| DAPSA, range 0–164‡ | 0.039 (−0.005, 0.084) | 0.080 | ||
| PASDAS | 2.684 (1.341, 4.026) | <0.001 | 1.506 (0.240, 2.771) | 0.020 |
| MASES, range 0–13 | 0.152 (−0.050, 0.355) | 0.14 | ||
| IGA, VAS 0–100 mm | 0.047 (−0.004, 0.097) | 0.068 | ||
| PGA, VAS 0–100 mm | 0.052 (0.028, 0.076) | <0.001* | ||
| Pain, VAS 0–100 mm | 0.051 (0.025, 0.077) | <0.001 | 0.034 (−0.001, 0.068) | 0.058 |
| Fatigue, VAS 0–100 mm | 0.033 (0.015, 0.052) | 0.001 | ||
| Morning stiffness, hour | 0.485 (−0.023, 0.992) | 0.061 | ||
| Sleep disturbance, NRS 0–10 | 0.363 (0.155, 0.572) | 0.001 | ||
| Anxiety/depression, range 1–3 | 0.766 (−0.309, 1.841) | 0.16 | ||
| MHAQ, range 0–3 | 2.642 (1.113, 4.170) | 0.001 | ||
| Exercise ≥1 time per week | −1.286 (−2.549, −0.023) | 0.046 | ||
| Power Doppler signal present in any joints, entheses or tendons | −0.315 (−1.589, 0.959) | 0.63 | ||
| Power Doppler sum score in joints, entheses and tendons (range 0–347) | −0.262 (−0.598, 0.074) | 0.13 | ||
| Comorbidities ≥1 | 0.485 (−0.804, 1.773) | 0.458 | ||
| PASI, range 0-72 | 0.587 (0.445, 0.728) | <0.001 | 0.560 (0.420, 0.700) | <0.001 |
| Current bDMARD | −0.382 (−1.716, 0.952) | 0.57 | ||
| Current csDMARD | −0.898 (−2.187, 0.391) | 0.17 | ||
| Ever bDMARD | −0.157 (−1.463, 1.150) | 0.81 | ||
| Ever csDMARD | −0.215 (−2.277, 1.848) | 0.84 | ||
*Not in the final multivariate model.
†With PASDAS in the model.
‡With DAPSA instead of PASDAS in the model only age, PASI and comorbidities remained but not DAPSA was statistically significantly associated with DLQI.
bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; IGA, Investigator Global Assessment; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MHAQ, Modified Health Assessment Questionnaire; NRS, Numeric Rating Scale; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area Severity Index; PGA, Patient Global Assessment; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.